Pediatric lipid screening

Clinical Lipidology

Volumn 8, Issue 4, 2013, Pages 425-436

  McNeal, Catherine J ^a   Underland, Lisa ^a   Wilson, Don P ^b   Blackett, Piers R ^c  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b Scott and White Healthcare ^*  (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

atherosclerosis; cardiovascular disease; dyslipidemia; guidelines; lipid; primary prevention; risk factor; youth

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHILDHOOD DISEASE; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOSITY; HUMAN; HYPERLIPIDEMIA; LIPID TRANSPORT; LIPOPROTEIN DEFICIENCY; PATIENT EDUCATION; PEDIATRICS; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UNITED STATES;

EID: 84882247538     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.13.42     Document Type: Review

References (75)

1. Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 123(8), 933-944 (2011
2. Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115(5), e69-e171 (2007
3. Mahoney EM, Wang K, Cohen DJ et al. REACH Registry Investigators. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ. Cardiovasc. Qual. Outcomes 1(1), 38-45 (2008
4. Expert Panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics 128(Suppl. 5), S213-S256 (2011
5. Humphries SE. Guidelines for the identification and management of patients with familial hypercholesterolaemia (FH): Are we coming to a consensus? Atheroscler. Suppl. 12(2), 217-220 (2012
6. Qureshi N, Humphries SE, Seed M, Rowlands P, Minhas R; NICE Guideline Development Group. Identification and management of familial hypercholesterolaemia: What does it mean to primary care? Br. J. Gen. Pract. 59(567), 773-776 (2009
7. Watts GF, Sullivan DR, Poplawski N et al. Familial hypercholesterolaemia: A model of care for Australasia. Atheroscler. Suppl. 12(2), 221-263 (2011
8. O'Kane MJ, Menown IB, Graham I et al. The detection of heterozygous familial hypercholesterolemia in Ireland. Adv. Ther. 29(5), 456-463 (2012
9. Watts GF, Lewis B, Sullivan DR. Familial hypercholesterolemia: A missed opportunity in preventive medicine. Nat. Clin. Pract. Cardiovasc. Med. 4(8), 404-405 (2007
10. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of Type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J. Clin. Endocrinol. Metab. 89(6), 2601-2607 (2004
11. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52(7), 1544-1568 (1973
12. Wiesbauer F, Blessberger H, Azar D et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). Eur. Heart J. 30(9), 1073-1079 (2009
13. Gaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R. Atherosclerosis and Metabolic Diseases Study Group. Practical guidelines for familial combined hyperlipidemia diagnosis: An update. Vasc. Health Risk Manag. 3(6), 877-886 (2007
14. Goldberg AC, Hopkins PN, Toth PP et al. Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(Suppl. 3), S30-S37 (2011
15. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(Suppl. 3), S9-S17 (2011
16. Daniels SR, Gidding SS, de Ferranti SD. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Pediatric aspects of familial hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(Suppl. 3), S7-S30 (2011
17. Dalpino FB, Menna-Barreto L, de Faria EC. Influences of sex and age on biological rhythms of serum lipids and lipoproteins. Clin. Chim. Acta 406(1-2), 57-61 (2009
18. Report of the National Cholesterol Expert Panel on detection, evaluation, and treatment of high cholesterol in adults. Arch. Intern. Med. 148(1), 36-39 (1988
19. National Cholesterol Education Program (NCEP): Highlights of the report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 89(3), 495-501 (1992
20. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227-239 (2004
21. Kavey RE, Alada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association Expert Panel on population and prevention science; the councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing, and the kidney in heart disease; and the Interdisciplinary Working Group on quality of care and outcomes research; endorsed by the American Academy of Pediatrics. Circulation 114(24), 2710-2738 (2006
22. Daniels SR, Greer FR. Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 122(1), 198-208 (2008
23. McCrindle BW, Kwiterovich PO, McBride PE, Daniels SR, Kavey RE. Guidelines for lipid screening in children and adolescents: Bringing evidence to the debate. Pediatrics 130(2), 353-356 (2012
24. Newman TB, Pletcher MJ, Hulley SB. Overly aggressive new guidelines for lipid screening in children: Evidence of a broken process. Pediatrics 130(2), 349-352 (2012
25. Mitka M. Experts question recommendations for universal lipid screenings in children. JAMA 308(8), 750-751 (2012
26. Kwiterovich PO, Gidding SS. Universal screening of cholesterol in children. Clin. Cardiol. 35(11), 662-664 (2012
27. Schroeder AR, Redberg RF. Cholesterol screening and management in children and young adults should start early - NO! Clin. Cardiol. 35(11), 665-668 (2012
28. Cui Y, Blumenthal RS, Flaws et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 161(11), 1413-1419 (2001
29. Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: The Bogalusa Heart Study. Pediatrics 118(1), 201-206 (2006
30. Rainwater DL, McMahan CA, Malcom GT et al. Lipid and apolipoprotein predictors of atherosclerosis in youth: Apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. The PDAY Research Group. Arterioscler. Thromb. Vasc. Biol. 19(3), 753-761 (1999
31. Steinberger J, Daniels SR; American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young); American Heart Association Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Obesity, insulin resistance, diabetes, and cardiovascular risk in children: An American Heart Association scientific statement from the atherosclerosis, hypertension, and obesity in the Young Committee (Council on cardiovascular disease in the young) and the Diabetes Committee (Council on nutrition, physical activity, and metabolism). Circulation 107(10), 1448-1453 (2003
32. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. Med. 338(23), 1650-1656 (1998
33. McMahan CA, Gidding SS, Viikari JS et al. Association of pathobiologic determinants of atherosclerosis in youth risk score and 15 year change in risk score with carotid artery intima-media thickness in young adults (from the Cardiovascular Risk in Young Finns Study). Am. J. Cardiol. 100(7), 1124-1129 (2007
34. Magnussen CG, Venn A, Thomson R et al. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study. J. Am. Coll. Cardiol. 53(10), 860-869 (2009
35. McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: Implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation 117(9), 1216-1227 (2008
36. Bao W, Srinivasan SR, Wattigney WA, Berenson GS. Usefulness of childhood low-density lipoprotein cholesterol level in predicting adult dyslipidemia and other cardiovascular risks. The Bogalusa Heart Study. Arch. Intern. Med. 156(12), 1315-1320 (1996
37. Lauer RM, Lee J, Clarke WR. Predicting adult cholesterol levels from measurements in childhood and adolescence: The Muscatine Study. Bull. N. Acad. Med. 65(10), 1127-1142 (1989
38. Webber LS, Srinivasan SR, Wattigney WA, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study. Am. J. Epidemiol. 133(9), 884-899 (1991
39. Raitakari OT, Juonala M, Kahonen M et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: The Cardiovascular Risk in Young Finns Study. JAMA 290(17), 2277-2283 (2003
40. Pletcher MJ, Bibbins-Domingo K, Liu K et al. Nonoptimal lipids commonly present in young adults and coronary calcium later in life: The CARDIA (Coronary Artery Risk Development in Young Adults) study. Ann. Intern. Med. 153(3), 137-146 (2010
41. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 40(12), 2117-2121 (2002
42. Wiegman A, Hutten BA, de Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial. JAMA 292(3), 331-337 (2004
43. Rodenburg J, Vissers MN, Wiegman A et al. Statin treatment in children with familial hypercholesterolemia: The younger, the better. Circulation 116(6), 664-668 (2007
44. Gillman MW, Daniels SR Is universal pediatric lipid screening justified? JAMA 307(3), 259-260 (2012
45. US Preventive Services Task Force. Screening for Lipid Disorders in Children: Recommendation Statement. Agency for Healthcare Research and Quality, MD, USA (2007
46. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168(1), 1-14 (2003
47. Psaty BM, Rivara FP. Universal screening and drug treatment of dysplipdemia in children and adolescents. JAMA 307(3), 257-258 (2012
48. Heneghan C. Considerable uncertainty remains in the evidence for primary prevention of cardiovascular disease [editorial]. Cochrane Database Syst. Rev. 14(8), ED000017 (2011
49. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 380(9841), 565-571 (2012
50. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J. Am. Coll. Cardiol. 59(6), 572-582 (2012
51. Mitka M. Some question use of statins to reduce cardiovascular risks in healthy women. JAMA 307(9), 893-894 (2012
52. Preiss D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 305(24), 2556-2564 (2011
53. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 375(9716), 735-742 (2010
54. Culver AL, Ockene IS, Balasubramanian R et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med. 172(2), 144-152 (2012
55. Sattar N, Taskinen MR. Statins are diabetogenic - myth or reality? Atheroscler. Suppl. 13(1), 1-10 (2012
56. Bhatia L, Byrne CD. There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk. Evid. Based Med. 15(3), 84-85 (2010
57. Lazar LD, Pletcher MJ, Coxson PG, Bibbins- Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation 124(2), 146-153 (2011
58. Tonelli M, Lloyd A, Clement F et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: A meta-analysis. CMAJ 183(16), e1189-e1202 (2011
59. Conly J, Clement F, Tonelli M et al. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. CMAJ 183(16), e1180-e1188 (2011
60. Greving JP, Visseren FL, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: Whom to treat? Cost-effectiveness analysis. BMJ 342, d1672 (2011
61. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: A systematic review and cost-effectiveness analysis. Health Technol. Assess. 4(29), 1-123 (2000
62. McNeal CJ, Dajani T, Wilson D, Cassidy- Bushrow AE, Dickerson JB, Ory M. Hypercholesterolemia in youth: Obstacles and opportunities to prevent premature atherosclerotic cardiovascular disease. Curr. Atheroscler. Rep. 12(1), 20-28 (2010
63. McNeal CJ, Wilson DP, Christou D, Bush RL, Shepherd LG, Santiago J. The use of surrogate vascular markers in youth at risk for premature cardiovascular disease. J. Pediatr. Endocrinol. Metab. 22(3), 195-211 (2009
64. Williams CL, Hayman LL, Daniels SR et al. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 106(9), 143-160 (2002
65. Gidding SS, Daniels SR, Kavey RE; Expert Panel on Cardiovascular Health and Risk Reduction in Youth. Developing the 2011 integrated pediatric guidelines for cardiovascular risk reduction. Pediatrics 129(5), e1311-e1319 (2012
66. Dawson JD, Sonka M, Blecha MB, Lin W, Davis PH. Risk factors associated with aortic and carotid intima-media thickness in adolescents and young adults: The Muscatine Offspring Study. J. Am. Coll. Cardiol. 53(24), 2273-2279 (2009
67. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 104(23), 2815-2819 (2001
68. Paul TK, Chen W, Srinivasan SR, He J, Berenson GS. Contrast of the impact of multiple cardiovascular risk factors on the femoral and carotid intima-media thickness in asymptomatic young adults: The Bogalusa Heart Study. Atherosclerosis 216(2), 359-364 (2011
69. Strong JP, Malcom GT, McMahan CA et al. Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from the pathobiological determinants of atherosclerosis in youth study. JAMA 281(8), 727-735 (1999
70. McMahan CA, Gidding SS, Fayad ZA et al. Risk scores predict atherosclerotic lesions in young people. Arch. Intern. Med. 165(8), 883-890 (2005
71. Gidding SS, McMahan CA, McGill HC et al. Prediction of coronary artery calcium in young adults using the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) risk score: The CARDIA study. Arch. Intern. Med. 166(21), 2341-2347 (2006
72. Magnussen CG, Raitakari OT, Thomson R et al. Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood: Evidence from the Childhood Determinants of Adult Health (CDAH) study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study. Circulation 117(1), 32-42 (2008
73. Juonala M, Magnussen CG, Venn A et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: The cardiovascular risk in Young Finns Study, the Childhood Determinants of Adult Health study, the Bogalusa Heart study, and the Muscatine study for the International Childhood Cardiovascular cohort (i3C) consortium. Circulation 122(24), 2514-2520 (2010
74. Horton JD, Cohen JC, Hobbs HH. PCSK9: A convertase that coordinates LDL catabolism. J. Lipid Res. 50(Suppl.), S172-S177 (2009
75. Ritchie SK, Murphy EC, Ice C et al. Universal versus targeted blood cholesterol screening among youth: The CARDIAC project. Pediatrics 126(2), 260-265 (2010